Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRACOR: Cangrelor in Elective PCI
NCT06089577Phase 4
Key facts
- Status
- Recruiting
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Countries
- 1
- Sponsor
- University of Naples Federico II
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Drugs
- cangrelor
- Conditions
- Chronic Coronary Syndrome (CCS)
01
Overview
Phase 4, randomised, open-label trial of cangrelor in Chronic Coronary Syndrome (CCS) (2 arms), sponsored by University of Naples Federico II. Primary endpoint: Incidence of microvascular dysfunction. Started Nov 2023; status: recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Cangrelor
Cangrelor IV + PCI + Clopidogrel post-proc
Control
Clopidogrel + PCI
03
Who it enrols
Adult patients with chronic coronary syndromes, naive to P2Y12 inhibitors, undergoing elective PCI of a functionally significant intermediate coronary artery stenosis.
04
Endpoints
Primary
Incidence of microvascular dysfunction
Secondary
Periprocedural platelet reactivity
Incidence of Periprocedural myocardial infarction
Incidence of Residual Angina
Incidence of residual ischemia
Beyond the preview
Go deeper on NCT06089577.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089577.